Moderna has selected the green fields of Oxfordshire to build its new logo and production plant.
Moderna plans to open the site, called the Moderna Innovation and Technology Centre (MITC), on the Harwell Science and Innovation Campus, which is near the village of Harwell, UK, 16 miles south of the city of Oxford. studies and progression functions and a production facility, Moderna said in a submission to Endpoints News.
The facility will have the capacity to manufacture its Covid-19 vaccine, as well as other respiratory vaccines that may also be approved, a Moderna spokesperson told Endpoints in an email. The site will also be able to increase production to respond to any potential public health threats that might arise. The exact charge of the assignment is confidential, but the Moderna spokesperson said the company will “invest millions of dollars in the U. K. to build this production facility and think tank. “
Moderna plans to start the structure this year, with production coming online in 2025; however, the allocation is still subject to local plans and other approvals. Moderna did not give Endpoints a precise employment figure, but said the allocation would create “hundreds” of jobs.
“Once built, our facility in Harwell will leverage mRNA science that aims to expand and deliver to the UK public cutting-edge vaccines that address the emerging respiratory virus threats facing our population,” Darius Hughes, Moderna’s UK chief executive, told reporters. release. .
Moderna aimed to bolster its presence in the UK for some time, and the UK government and Moderna issued initial plans for a in June last year. In December, plans for MITC were finalized, and the deal also added a finalized 10-year partnership. to bring the country’s mRNA ecosystem to life.
However, Moderna only focuses on the UK. It has already invested more than $500 million to expand its presence in Spain, and may turn to Japan for some other production site, according to media reports.
Adaptimmune merges with TCR² Therapeutics to create a T-cell treatment developer for counterfeit tumors.
The all-action agreement brings together the main applicants from the two companies: Adaptimmune’s afami-cel, which targets MAGE-A4, and TCR²’s gavo-cel, which targets mesothelin, as well as a portfolio of applicants designed with T-cell receptors, or TCRs. Unlike CAR-T therapies, TCR-T is limited to surface antigens, but can target antigens on internal cancer cells.
Unlock this story right away and sign up to have over 162,200 biopharmaceutical professionals read Endpoints daily, and it’s free.
When Hannah Sames was four years old, she was diagnosed with an ultra-rare genetic condition called giant axonal neuropathy. She is now 18 and her doctors have long expected her to be quadriplegic and doomed to an untimely death.
Instead, you can stand up, but with help. ” Even with his physical challenges, he is happy. She’s a sociable teenager and loves music,” said her mother, Lori Sames.
Unlock this article and others by subscribing to one of our paid plans.
Take a look at the 53 inhalers approved by the FDA to treat asthma and COPD from 1986 to 2020, and look for generic versions of just 4 of those brand-name products, and a developing hole where brands are likely to resist getting in, researchers from Georgetown, the University of Calgary, West Virginia University, and Harvard in a Health Affairs article published yesterday.
This lack of festival has meant decades of monopolies for successful inhalers distributing non-unusual remedies for asthma, COPD and others such as albuterol, budesonide, formoterol and fluticasone-salmeterol.
AbbVie executives touted a wave of Rinvoq systems at Coyen’s annual healthcare convention Tuesday as they prepare for a tougher Humira war this time this year.
Since its first approval for rheumatoid arthritis in 2002, Humira has one of the most sensible distributors in the industry, adding an extensive list of indications ranging from ulcerative colitis to ankylosing spondylitis. Humira’s first biosimilar, Amgen’s Amjevita, was introduced last January. , and AbbVie executives announced at the last quarterly call that they expected a 37% drop in Humira sales this year.
South through Southwest, abbreviated SXSW and also called South By, has a symbol of several decades of avant-garde culture and hipster mix. So what are pharmaceutical corporations and fitness agencies doing there?Integrate, actually.
No longer just for music and movie enthusiasts or virtual and tech futurists, today’s SXSW manages a diversity of industries and themed tracks, and adds those that focus on health. While SXSW Health and Medtech’s main track is not new, its relevance to pharmaceutical marketers continues to grow.
Unlock this story right away and sign up to have over 162,200 biopharmaceutical professionals read Endpoints daily, and it’s free.
Genentech expands its commitment, and increases its promise, to combat systemic racism in health care and education. Roche and its Genentech Foundation recently committed $17 million to 31 grantees, a 40% increase since its last circular of $12 million in investment commitments in 2022.
It also prioritizes varied and representative teams, with 94% of beneficiary teams led or co-led by other people of color. That’s 70% last year.
Unlock this story right away and sign up to have over 162,200 biopharmaceutical professionals read Endpoints daily, and it’s free.
Luxembourg-based Covis Pharma has been in a tug-of-war with the FDA over whether to withdraw its questionable preterm birth drug Makena, which won accelerated approval in 2011 but failed its confirmatory test in 2018.
After two communication failures, Covis now waving the white flag and agreeing to withdraw the drug from the market, according to documents released this afternoon.
Covis’ resolution follows a 14-1 vote through the FDA’s Urologic, Reproductive and Obstetric Drug Advisory Committee last October to withdraw the drug, which was unable to verify the drug’s benefits for young children or mothers.
Following its European approval last September, Bristol Myers Squibb will not launch Opdualag, an infusion of the pharmaceutical giant’s Opdivo and the new antibody relatlimab, in Germany due to value pressures. The drug has been approved to treat complex melanoma in adults and adolescents 12 years of age and older.
According to a Bristol Myers spokesman, Opdualag will be announced in Germany “for the foreseeable future,” as the country’s 2010 drug pricing law guarantees that the pharmaceutical giant “sees no option to get an assessment of the benefits of G-BA. “[Gemeinsamer Bundesausschuss] for Opdualag.
Gilead joins the list of multimillion-dollar expansions of big construction names in Ireland.
The pharmaceutical company is expanding its facilities located in the city of Carrigtwohill, Ireland, in County Cork, in the south of the country. Gilead plans to invest forty-five million euros ($47. 5 million) in the expansion that will be used to build a square-foot warehouse, according to an email sent to Endpoints News. The investment will result in a slight increase in its workforce in Cork, a Gilead spokesman said, but no additional main points were given beyond that.
© Endpoints Company 2023
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.